DBX ETF Trust has released its latest financial report, showcasing a strong position in the investment sector. The filing indicates a total asset value of approximately $1.14 billion and net assets of around $1.06 billion as of August 31, 2026. This performance is essential as it reflects the trust's ongoing stability and management effectiveness in a competitive market.
As an investment entity, DBX ETF Trust operates in a sector that requires constant adaptation to market conditions. The reported figures suggest that the trust is successfully navigating these challenges, which could influence investor confidence and competitive dynamics within the industry.
Background
DBX ETF Trust, incorporated in Delaware, is an investment entity focusing on managing exchange-traded funds (ETFs). The trust is known for its Xtrackers International Real Estate ETF, which is part of its portfolio. The latest SEC filing, dated October 29, 2026, is part of a series of recent filings that include multiple NPORT-P submissions, indicating ongoing regulatory compliance and transparency.
What the Filing Says
The recent filing details the financial status of DBX ETF Trust as of August 31, 2026. It reports total assets of $1,138,309,568.65 and total liabilities of $80,815,005.87, leading to net assets of $1,057,494,562.78. The filing states, "This is not a final filing," suggesting that further updates may follow.
Impact
This financial disclosure may affect various stakeholders, including investors, analysts, and competitors in the investment sector. Investors may view the trust's solid financials as a sign of stability, potentially influencing their investment decisions. Competitors in the real estate investment sector might reassess their strategies in light of DBX ETF Trust's performance and asset management practices.
What's Next
The filing does not specify what happens next, leaving stakeholders to anticipate further updates or filings from DBX ETF Trust in the future.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






